Drug Profile
OMTX 001
Alternative Names: OMTX-001Latest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Oncomatryx
- Class Antineoplastics; Cystatins
- Mechanism of Action Cathepsin B inhibitors; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Triple negative breast cancer
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Spain
- 27 Jul 2016 Preclinical development is ongoing in Spain
- 26 Sep 2014 Preclinical trials in Triple negative Breast cancer in Spain (unspecified route)